LGC. (11/25/20). "Press Release: LGC Offers Regulated Bioanalysis on the Sciex TripleTOF 6600 High-Resolution Mass Spectrometry Platform". London.

	Region	Fordham, Cambridgeshire
	Country	United Kingdom (GB)
	Organisation	LGC (Group)
	Organisation 2	AB Sciex LLC (d/b/a Sciex)
	Group	Danaher (Group)
	Product	AB Sciex TripleTOF® 6600 System
	Product 2	mass spectrometry-based analysis of biopharmaceutical
	Person	Quigley, Julian (LGC Group 201910 Media Relations + Social Media Manager)
	Person 2	Krishnan, Mani (Danaher 202004 VP Global Biopharma + Capillary Electrophoresis at Sciex)

LGC is pleased to announce the extension of its regulated bioanalytical LC-MS service through the implementation of a high-resolution mass spectrometer, the SCIEX TripleTOF® 6600 LC-MS/MS System.

With enhanced levels of selectivity and mass accuracy, this platform offers an alternative tool for the quantification of therapeutics and biomarkers from within complex biological matrices. Following a successful computerised system validation, LGC’s Drug Development Solutions team (DDS) is now able to offer high-resolution mass spectrometry as a regulated service at their GLP/GCP-accredited facility in Cambridge (Fordham), UK.

Rachel Green, Operations Director, Drug Development Solutions, LGC comments, “Bioanalytical utilisation of high-resolution mass spectrometry has gained traction within the discovery space, offering benefits such as rapid generation of rich data sets and quan/qual workflows. Popularity however, within drug development has always lagged behind. With recent technological advancements that have led to comparable sensitivity to triple quadrupole mass spectrometry; these platforms are now becoming a lot more attractive as a bioanalytical tool. We are very excited to offer this service to our customers within a regulatory environment in support of their drug development programs.”

“For more than 50 years, SCIEX has been a proven leader in bioanalysis quant,” says Mani Krishnan, vice president and general manager, CE & Biopharma, SCIEX. “The TripleTOF® 6600 Accurate Mass System is a powerful, flexible and reliable platform, which will expand LGC’s capabilities, and enhance their ability to help customers accelerate drugs to market.”

Rob Wheller, Associate Scientific Director, Drug Development Solutions, at LGC adds, “With the enhanced selectivity of high-resolution mass spectrometry, we are able to eliminate more interferences from our targeted analysis approaches, which we’ve found can lead to greater assay detection limits. Nowhere is this more pertinent than with protein digestion workflows, pushing the limits of sensitivity closer to those achievable with more complex immunoaffinity purifications. In addition, it opens the door to middle-down and top-down quantitation approaches, which are gaining popularity within the industry, through their ability to shed more light on the in vivo fate of dosed biotherapeutics and protein biomarkers. This platform is a fantastic addition to our toolkit and boosts our capability as a Protein LC-MS Centre of Excellence.”

www.lgcgroup.com

Notes for Editors

Rachel Green is available for interview, by arrangement
Images are available on request

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed ground-breaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher family of global life science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com

About LGC Group

LGC is a global leader in the life science tools sector, providing mission critical components to customers across clinical diagnostics, pharmaceutical, research & government, food and other applied markets.

LGC provides a comprehensive range of specialty genomic analysis tools, measurement tools and supply chain assurance solutions, underpinned by leading analytical and measurement science capabilities. It holds a number of national and international roles, including the UK Government Chemist programme and serving as the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement.

LGC's scientific tools and solutions form an essential part of customer quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research. Its 3,800+ employees include internationally-recognised scientists who are experts in their field. Headquartered in London, LGC operates out of 17 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.

LGC was founded in 1842. It has been privately-owned since 1996 and has diversified through internal investment and acquisitions to be an international leader in its chosen markets. LGC is now owned by funds affiliated to Cinven, Astorg and ADIA.

For more information, please visit www.lgcgroup.com

About LGC’s Drug Development Solutions (DDS)

With 20+ years working to GLP and GCP in one of the world’s most extensive bioanalytical facilities, LGC’s team of scientists are dedicated to providing on time, high quality data to help make critical decisions on the safety and efficacy of customer molecules.

LGC’s DDS facility in Cambridge (Fordham) is home to LGC’s specialist teams in the fields of immunogenicity and Protein LC-MS. Supported by the latest immunochemistry and mass spectrometry technologies; LGC has developed in-depth expertise in these key areas of analytical science with successful contributions to biopharmaceutical research.

For more information, visit www.lgcgroup.com/dds or contact pharma@lgcgroup.com

Media contact

Julian Quigley
Media Relations & Social Media Manager, LGC
+44 (0)20 8943 8491
Julian.quigley@lgcgroup.com

Record changed: 2023-06-05